Finance / Belgium
Lucentis Made Available
October 2007 | Industry NewsThousands of Belgian patients could be saved from going blind after US firm Genentech's controversial drug Lucentis (ranibizumab), which treats wet age-related macular degeneration (AMD), was made available in the country, with the state picking up the lion's share of the cost.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
